{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:11:54Z","timestamp":1780467114809,"version":"3.54.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The prevalence of herpes zoster (HZ) is high in patients with rheumatic diseases. Systemic lupus erythematosus (SLE) doubles the risk for developing HZ. However, little is known about natural humoral immunity against varicella zoster virus (VZV) in patients with SLE. Hence, we compared VZV IgG antibody concentrations in a group of SLE patients with healthy controls and patients with rheumatoid arthritis (RA). Methods: n = 56 patients with SLE, n = 54 patients with RA, and n = 56 healthy controls were included in this study. The VZV IgG antibody concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The antibody concentrations were compared between the groups. Results: Overall IgG antibody titers for VZV in SLE patients were comparable to healthy controls but higher when compared to patients with rheumatoid arthritis (p = 0.0012). In consequence, antibody levels in controls were higher than in RA patients (p = 0.0097). Stratification by age revealed highest titers among SLE patients in the fourth life decade (p = 0.03 for controls, p = 0.0008 for RA patients) whereas RA patients in their sixth decade had the lowest antibody concentration (p = 0.03 for controls, p = 0.04 for SLE patients). Regarding the individual HZ history, antibody levels of SLE patients with a positive history exceeded all other groups. Conclusions: Although humoral VZV immunity in SLE patients is comparable to healthy controls it seems to be pronounced in young SLE patients between 30 and 39. The lowest VZV IgG levels were found in RA patients. HZ seems to induce antibody production, particularly in patients with SLE. Immunological processes might contribute to VZV antibody levels in SLE patients, but further investigations are needed to substantiate this hypothesis. Even though the increased HZ prevalence seems to be independent of humoral immunity in SLE patients, reduced humoral immunity might contribute to HZ in RA patients. The available HZ subunit vaccination might be an appropriate way to reduce the HZ risk in patients with rheumatic diseases.<\/jats:p>","DOI":"10.3390\/vaccines9040325","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T10:44:01Z","timestamp":1617273841000},"page":"325","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Humoral Immunity to Varicella Zoster Virus in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Compared to Healthy Controls"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-0754","authenticated-orcid":false,"given":"Marco","family":"Krasselt","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Clinic for Endocrinology, Nephrology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Baerwald","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Clinic for Endocrinology, Nephrology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5129-0875","authenticated-orcid":false,"given":"Uwe G.","family":"Liebert","sequence":"additional","affiliation":[{"name":"Institute for Virology, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Seifert","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Clinic for Endocrinology, Nephrology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology, University of Leipzig, Liebigstr. 20, 04103 Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What Does Epidemiology Tell Us About Risk Factors for Herpes Zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/infdis\/jiz652","article-title":"The epidemiology of herpes zoster in immunocompetent, unvaccinated adults >\/= 50 years old: Incidence, complications, hospitalization, mortality, and recurrence","volume":"222","author":"Tseng","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: Population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"Br. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: A population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","article-title":"Risk of herpes zoster in patients with underlying diseases: A retrospective hospital-based cohort study","volume":"39","author":"Hata","year":"2011","journal-title":"Infection"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1002\/art.38804","article-title":"Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases","volume":"66","author":"Rondaan","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk factors for herpes zoster: A systematic review and meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: Analysis of disease characteristics and disease-modifying antirheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_13","first-page":"e014032","article-title":"Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: A case-control study in Asia","volume":"7","author":"Liao","year":"2017","journal-title":"Br. Med. J. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A Systematic review and meta-analysis of infection risk with small molecule jak inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_15","unstructured":"Firestein, G., Budd, R., Sherine, E.G., Iain, B.M., and O\u2032Dell, J. (2020). Firestein & Kelley\u2032s Textbook of Rheumatology-E-Book, Elsevier."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0002-9343(80)90003-0","article-title":"Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus","volume":"69","author":"Blaese","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_17","first-page":"1214","article-title":"Sex, symptom severity, and quality of life in rheumatology","volume":"26","author":"Krasselt","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (Vzv)-Specific cell-mediated immunity with increasing age and boosting with a high-dose Vzv vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1177\/0961203318770535","article-title":"Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity","volume":"27","author":"Rondaan","year":"2018","journal-title":"Lupus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.49.8.630","article-title":"High incidence of herpes zoster in patients with systemic Lupus erythematosus: An immunological analysis","volume":"49","author":"Nagasawa","year":"1990","journal-title":"Ann. Rheumatol. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780240402","article-title":"Polyclonally yriggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic Lupus erythematosus and primary Sjogren\u2019s syndrome","volume":"24","author":"Fauci","year":"1981","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cuadrado, M.J., Calatayud, I., Urquizu-Padilla, M., Wijetilleka, S., Kiani-Alikhan, S., and Karim, M.Y. (2019). Immunoglobulin abnormalities are frequent in patients with Lupus nephritis. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0079-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1006\/jaut.1998.0236","article-title":"Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease","volume":"11","author":"Hassan","year":"1998","journal-title":"J. Autoimmun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.47.7.536","article-title":"An igg subclass imbalance in connective tissue disease","volume":"47","author":"Kay","year":"1988","journal-title":"Ann. Rheumatol. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"370516","DOI":"10.1155\/2012\/370516","article-title":"Epstein-barr virus and systemic Lupus erythematosus","volume":"2012","author":"Draborg","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/ard.49.9.657","article-title":"Rheumatoid arthritis, malignancy, and paraproteins","volume":"49","author":"Kelly","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3899\/jrheum.130905","article-title":"Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis","volume":"41","author":"Scarsi","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s10067-019-04563-9","article-title":"Humoral immunity to varicella zoster virus is altered in patients with rheumatoid arthritis","volume":"38","author":"Krasselt","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: An overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/infdis\/jiz653","article-title":"How little we know herpes zoster","volume":"222","author":"Harpaz","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kraaij, T., Arends, E.J., Van Dam, L.S., Kamerling, S.W.A., Van Daele, P.L.A., Bredewold, O.W., Ray, A., Bakker, J.A., Scherer, H.U., and Huizinga, T.J.W. (2020). Long-Term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic Lupus erythematosus: 2-year results. Nephrol. Dial. Transpl., online ahead of print.","DOI":"10.1136\/lupus-2020-eurolupus.171"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/JVI.02592-07","article-title":"Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia","volume":"82","author":"Reichelt","year":"2008","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMe1700720","article-title":"A baffling association between malaria resistance and the risk of multiple sclerosis","volume":"376","author":"Korn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrrheum.2009.180","article-title":"Rejuvenating the immune system in rheumatoid arthritis","volume":"5","author":"Weyand","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"Vzv-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The Shez study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jdermsci.2012.10.015","article-title":"An inverse correlation of Vzv skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain","volume":"69","author":"Asada","year":"2013","journal-title":"J. Derm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jdermsci.2015.05.011","article-title":"Vzv skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia","volume":"79","author":"Imoto","year":"2015","journal-title":"J. Derm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21645515.2018.1514228","article-title":"Herpes zoster vaccination in systemic lupus erythematosus: The current status","volume":"15","author":"Mok","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00296-016-3608-y","article-title":"Low vaccination rates among patients with rheumatoid arthritis in a german outpatient clinic","volume":"37","author":"Krasselt","year":"2017","journal-title":"Rheumatol Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00393-017-0410-5","article-title":"Insufficient vaccination rates in patients with systemic Lupus erythematosus in a german outpatient clinic","volume":"77","author":"Krasselt","year":"2018","journal-title":"Z. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Schmedt, N., Schiffner-Rohe, J., Sprenger, R., Walker, J., Von Eiff, C., and H\u00e4ckl, D. (2019). Pneumococcal vaccination rates in immunocompromised patients\u2014A cohort study based on claims data from more than 200.000 patients in Germany. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220848"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/rheumatology\/key120","article-title":"Vaccination coverage in systemic Lupus erythematosus\u2014A cross-sectional analysis of the German long-term study (Lula Cohort)","volume":"57","author":"Chehab","year":"2018","journal-title":"Rheumatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of eular recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheumatol. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_47","unstructured":"RKI (2020). St\u00e4Ndige Impfkommission: Empfehlungen Der St\u00e4Ndigen Impfkommission, Robert Koch-Institut."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in hiv-infected adults: A phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"ref_53","first-page":"S417","article-title":"Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (Hz\/Su) in adults post renal transplant: A phase iii randomized clinical trial","volume":"4","author":"Vink","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","article-title":"Impfen bei Immundefizienz","volume":"62","author":"Wagner","year":"2019","journal-title":"Bundesgesundheitsbl."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-215925","article-title":"Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: A randomised placebo-controlled trial","volume":"78","author":"Mok","year":"2019","journal-title":"Ann. Rheumatol. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Co","year":"2020","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: A pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"Dagnew","year":"2021","journal-title":"Rheumatology"},{"key":"ref_60","unstructured":"Acharya, S., Raza, S., Pattanaik, D., and Howard, A. (2019). Safety of adjuvanted herpes zoster subunit vaccine (Hz\/Su, Shingrix) among patients with autoimmune inflammatory diseases. Arthritis & Rheumatology, Wiley."},{"key":"ref_61","unstructured":"K\u00e4llmark, H., Gullstrand, B., Nagel, J., Einarsson, J., J\u00f6nsson, G., Kahn, F., Kahn, R., Bangtsson, A., Bergstr\u00f6m, T., and Kapetanovic, M. (2020). Immunogenicity of adjuvanted herpes zoster subunit vaccine in rheumatoid arthritis patients treated with janus kinase inhibitors and controls: Preliminary results. Arthritis & Rheumatology, Wiley."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/325\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:25:43Z","timestamp":1760361943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/4\/325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["vaccines9040325"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9040325","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}